Vor Biopharma (Vor Biopharma) Debt-to-Equity : 0.24 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Vor Biopharma Debt-to-Equity?

Vor Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.83 Mil. Vor Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $31.83 Mil. Vor Biopharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $150.72 Mil. Vor Biopharma's debt to equity for the quarter that ended in Dec. 2023 was 0.24.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Vor Biopharma's Debt-to-Equity or its related term are showing as below:

VOR' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.66 Med: 0.16 Max: 0.38
Current: 0.24

During the past 6 years, the highest Debt-to-Equity Ratio of Vor Biopharma was 0.38. The lowest was -0.66. And the median was 0.16.

VOR's Debt-to-Equity is ranked worse than
60.24% of 1069 companies
in the Biotechnology industry
Industry Median: 0.15 vs VOR: 0.24

Vor Biopharma Debt-to-Equity Historical Data

The historical data trend for Vor Biopharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vor Biopharma Debt-to-Equity Chart

Vor Biopharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.38

0.08

0.16

0.24

Vor Biopharma Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial														0.16	0.17	0.18	0.21	0.24

Competitive Comparison of Vor Biopharma's Debt-to-Equity

For the Biotechnology subindustry, Vor Biopharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vor Biopharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vor Biopharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Vor Biopharma's Debt-to-Equity falls into.

Vor Biopharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Vor Biopharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.83	+	31.83)	/	150.724
	=	0.24

Vor Biopharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.83	+	31.83)	/	150.724
	=	0.24

Vor Biopharma (NAS:VOR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Vor Biopharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Vor Biopharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vor Biopharma (Vor Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vor Biopharma Inc (NAS:VOR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Cambridgepark Drive, Suite 101, Cambridge, MA, USA, 02140

Website

https://www.vorbio.com

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.

Executives

Eyal C. Attar	officer: Chief Medical Officer	535 BOYLSTON STREET, BOSTON MA 02116
5am Ventures Vi, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nathan D. Jorgensen	officer: Chief Financial Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Christopher Slapak	officer: Chief Medical Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Sadik Kassim	officer: Chief Technology Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Tirtha Chakraborty	officer: Chief Scientific Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Robert Ang	director, officer: President and CEO	C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
5am Partners Vi, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
David Charles Lubner	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Puretech Health Llc	10 percent owner	501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Daniella Beckman	director	C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
5am Opportunities I (gp), Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107